Non-HDL Cholesterol

Study Notes

Non-HDL-C represents the fraction of blood cholesterol in lipoproteins containing apo B (VLDL + LDL).
At triglyceride levels of 200-499 mg/dL, most cholesterol in VLDL is highly atherogenic.
Non-HDL-C is considered a secondary goal of lipid therapy when triglyceride levels are between 200-499 mg/dL.
Non-HDL-C can be measured in a random blood sample (without fasting).
Non-HDL-C is calculated by subtracting HDL-C from total cholesterol (TC).

Non-HDL-C goal is 30 mg/dL higher than LDL-C goal when triglyceride levels are between 200-499 mg/dL.

Atherogenic Index is not commonly used today, as it diverts priority from LDL-C.
It is calculated by dividing total cholesterol (TC) by HDL-C.
A desirable Atherogenic Index is < 5.

Plasma specimen with EDTA anticoagulant is preferred.
Patients should have a normal diet and exercise routine for at least 2 weeks before the test.
Blood specimen should be collected after an overnight fast of 10-14 hours.
Venous stasis should be minimal.
Avoid testing during or within 3 months following a serious illness.
Testing within 12 hours after myocardial infarction may be useful.
Stop taking drugs containing glycerol at least 24 hours before the test.

Measurement of LDL-C is used as a screening test during childhood, especially for those with a positive family history of dyslipoproteinemia or coronary heart disease.
Everyone over 20 should undergo lipid profile testing.
Follow-up lipid profile tests are recommended every 5 years for most people.
More frequent testing may be necessary if lipid profile parameters are not desirable or if there are other concerns about heart disease.